During the last session, MaxCyte Inc (NASDAQ:MXCT)’s traded shares were 0.37 million. The 52-week high for the MXCT share is $5.55, that puts it down -32.78 from that peak though still a striking 41.39% gain since the share price plummeted to a 52-week low of $2.45. The company’s market capitalization is $439.28M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 501.98K shares over the past three months.
MaxCyte Inc (MXCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. MXCT has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MaxCyte Inc (NASDAQ:MXCT) trade information
The stock’s 5-day price performance is -4.35%, and it has moved by -6.28% in 30 days. Based on these gigs, the overall price performance for the year is -4.13%. The short interest in MaxCyte Inc (NASDAQ:MXCT) is 4.19 million shares and it means that shorts have 6.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 47.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, MXCT is trading at a discount of -91.39% off the target high and -91.39% off the low.
MaxCyte Inc (MXCT) estimates and forecasts
Statistics show that MaxCyte Inc has underperformed its competitors in share price, compared to the industry in which it operates. MaxCyte Inc (MXCT) shares have gone down -13.81% during the last six months, with a year-to-date growth rate less than the industry average at -27.03% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.20%. While earnings are projected to return -14.67% in 2024.
MaxCyte Inc (NASDAQ:MXCT)’s Major holders
MaxCyte Inc insiders own 1.45% of total outstanding shares while institutional holders control 73.91%, with the float percentage being 75.00%. BLACKROCK INC. is the largest shareholder of the company, while 197.0 institutions own stock in it. As of 2024-03-31, the company held over 7.23 million shares (or 6.9714% of all shares), a total value of $30.29 million in shares.
The next largest institutional holding, with 6.56 million shares, is of CADIAN CAPITAL MANAGEMENT, LP’s that is approximately 6.3262% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $27.49 million.
